FDA Approves Wegovy Weight-Loss Pill: What to Know About Oral Semaglutide

This episode explains the first FDA-approved GLP-1 weight-loss drug in pill form: a once-daily oral semaglutide tablet (Wegovy pill) approved on December 22, 2025, with a U.S. launch in early January 2026. It clarifies that Rybelsus is also oral semaglutide but is only approved for type 2 diabetes, making Wegovy the first oral GLP-1 specifically approved for chronic weight management. Results from the 71-week OASIS 4 trial showed average weight loss of 13.6% at a 25 mg dose versus 2.2% with placebo, with adherent patients closer to 16.6%. The script highlights strict dosing requirements (empty stomach, ≤4 oz water, wait 30 minutes), similar nausea side effects to injections, expected similar pricing, and ongoing insurance and adherence hurdles while noting improved access for those avoiding injections.

00:00 Oral Wegovy Arrives

00:35 What Makes It New

00:53 OASIS 4 Results

01:33 How to Take It

01:58 Who Benefits Most

02:28 Caveats and Costs

02:49 Wrap Up

Retatrutide Phase 3 Results: Major A1C Drops and 16.8% Weight Loss in Type 2 Diabetes

This Medical News Update covers late-stage trial results for retatrutide, an investigational weight-loss and diabetes drug from Eli Lilly. On March 19, 2026, Lilly announced positive topline findings from the phase 3 TRANSCEND-T2D-1 trial in adults with type 2 diabetes, showing A1C reductions of 1.7% to 2.0% depending on dose and average weight loss of 16.8% at the 12 mg dose. The script explains retatrutide’s three-hormone mechanism (GLP-1, GIP, and glucagon) versus Ozempic/Wegovy (GLP-1) and Mounjaro/Zepbound (GLP-1 + GIP), cautions that superiority claims require head-to-head trials, notes common side effects like nausea, vomiting, and diarrhea, and emphasizes that FDA approval, coverage, and pricing would still take significant time if future results remain strong.

00:00 Big Drug News

00:36 Trial Results Breakdown

01:09 Why It Works

01:38 Headlines Caveat

02:03 What It Means

02:25 Side Effects Tradeoffs

02:38 When It Arrives

02:54 Bigger Picture Wrap

03:07 Final Sign Off

Why Ozempic Doesn’t Work for Everyone: The DNA Clue

This episode explains why Ozempic and similar weight-loss drugs don’t work the same for everyone, highlighting a Stanford University study published in April 2026. Researchers found that about 10% of people carry variants in a single gene affecting the enzyme PAM, which helps activate the body’s natural GLP-1 hormone—the system these medications rely on. With a sluggish PAM “switch,” GLP-1 may not be properly activated, which could help explain why some patients lose a lot of weight while others see minimal results. The host offers three takeaways: lack of response may not be willpower-related, genetic testing may eventually guide drug choice, and non-responders should discuss alternatives like SGLT2 inhibitors with a doctor. The episode notes this is early research and no approved predictive test exists yet.

00:00 Welcome and Setup

00:20 Ozempic Works Differently

00:43 The Gene Behind Response

01:18 Why GLP-1 Drugs Vary

01:38 Three Key Takeaways

02:17 Early Research Caveats

02:40 Wrap Up and Share

New Insights on Metabolic Health: Protect Your Brain and Heart

In this week's Medical News Update, we delve into recent research revealing how metabolic health impacts more than we realize. Key studies show that weight and blood pressure may contribute to dementia and heart issues, while redefining obesity could change our health landscape. We also highlight the effects of different types of fat on our blood vessels, the implications of post-meal blood sugar spikes on Alzheimer's risk, and the benefits of light physical activity for longevity. Keep your weight, blood pressure, and blood sugar in check with practical, everyday habits for long-term health benefits.

00:00 Introduction to This Week's Medical News Update

00:03 Metabolic Health and Dementia Risk

00:57 Redefining Obesity: Beyond BMI

01:45 The Role of Beige Fat in Heart Health

02:36 Blood Sugar Spikes and Alzheimer's Risk

03:31 Light Activity and Longevity

04:13 Conclusion: Interconnected Health Factors

#MetabolicHealth #DementiaPrevention #ObesityAwareness #BloodSugarControl #HealthyLifestyle

In this episode of Medical News Update, we discuss a recent study from Denmark examining the efficacy of high-dose inactivated influenza vaccines in adults aged 65 and older, particularly those with diabetes. The study reveals that high-dose vaccines lead to fewer cardiorespiratory and cardiovascular hospitalizations compared to standard-dose vaccines. While the exact benefits vary, the findings suggest that a high-dose approach is beneficial for older adults, especially those with long-standing diabetes. The episode also highlights current CDC recommendations for flu vaccination in older adults.

00:00 Introduction to Today's Topic

00:03 The Importance of Flu Vaccination for High-Risk Groups

00:17 Background on Influenza and Cardiovascular Risks

00:45 Details of the Danish Study (DANFLU-2)

01:45 Key Findings and Results

03:43 Implications for Clinical Practice

04:32 Conclusion and Final Thoughts

In this podcast episode, we discuss

• What “vascular-related dementia” means and why blood flow matters
• Why Mendelian randomisation strengthens causal inference, and where it can mislead
• The size of the BMI association and what the odds ratios imply
• How much of the link may run through blood pressure
• What listeners can do now: knowing your numbers and seeking realistic support

Sources mentioned

• The Journal of Clinical Endocrinology and Metabolism (online publication: 22 January 2026)
• Endocrine Society press release (22 January 2026)

Medical information in this podcast is for general education and is not personal medical advice.

00:00 Introduction to Today's Topic

00:03 New Research on Dementia and Body Weight

00:36 Understanding the Study Methodology

01:11 Key Findings: BMI and Dementia Risk

01:53 Blood Pressure's Role in Dementia

02:57 Implications for Everyday Life

03:28 Practical Advice for Reducing Dementia Risk

03:58 Conclusion and Further Reading

In this episode of Medical News Update, we explore innovative advancements in blood glucose regulation, focusing on smart insulin and dual-hormone therapy. Researchers at Indiana University School of Medicine have developed a fusion protein that combines insulin and glucagon, offering potential stability and effectiveness in managing blood sugar levels. Early animal studies show promise, but more research is needed before human clinical trials. Join us to learn how this could revolutionise type 1 diabetes care and make treatment more accessible globally.

 #DiabetesCare #InnovativeMedicine

In today's episode, we discuss an important alert from the WHO regarding semaglutide medicines like Ozempic, Rybelsus, and Wegovy, which are used for type 2 diabetes and weight management. A rare but serious side effect called non-arteritic anterior ischemic optic neuropathy (NAY-on), leading to sudden vision loss, has been linked to these drugs. We review what the European Medicines Agency has found, the risks involved, and what patients should do if they experience vision changes. Awareness and prompt action are crucial. Learn more about how to manage these risks while benefiting from these medications.

00:00 Introduction to Today's Episode

00:01 Understanding Semaglutide Medicines

00:17 Serious Side Effect Alert: NAY-on

00:49 Risk Assessment and Recommendations

01:45 Guidance for Patients on Semaglutide

02:19 Conclusion